Advanced Dentistry 2021 Prosthodontics 2021

conferenceseries.com

March 24-25, 2021

WEBINAR

Fabiano Vieira Vilhena, Volume 13



Fabiano Vieira Vilhena

TRIALS - Oral Health & Technologies, Brazil

New perspectives in antiviral and oral tissues repair technologies in times of COVID-19

ur lifestyle has contributed to a significant increase in oral diseases such as dental caries, dental erosion, tooth sensitivity and periodontal diseases. These issues are due to stress, unhealthy habits and an inadequate nutrition. Moreover, the risk of contamination and dissemination by SARS-CoV-2 has a strong link with the mouth. On the other hand, new technologies have been developed to fight against these problems, especially REFIX® technology (Dental Regeneration) and PHTALOX® technology (Antiviral and Soft Tissue Regeneration). Patients with sensitivity due to dentin exposure reported rapid pain relief from day one of using REFIX®-containing dentifrice. This technology is efficient not only to block dentine tubules but also to prevent against tooth decay and acid attacks. During brushing, the bioactive formula binds in the tooth, catching scattered particles found in the oral environment, mainly calcium and this complex forms a hybrid layer containing silicon-enriched hydroxyapatite. This biomimetic layer can resemble the tooth as an enamel-like. PHTALOX® Technology is a bioactive compound that acts on the production of reactive oxygen. In times of SARS-CoV-2, PHTALOX® has shown antimicrobial (antiviral) activity as well as improving oral health. It was also reported that patients who tested positive for COVID-19 experienced a significant reduction in their clinical symptoms (mouth ulcers, sore trougth, cough, among others) and their length of hospital stay after using the PHTALOX® mouthwash. To sum up, the results found with a regular use of REFIX® and PHTALOX® Technologies had a positive impact on patients, providing a healthier and pain-free daily life.

Biography

Vilhena graduated in Dentistry (1996) - Federal University of Alfenas - Brazil, Masters of Science in Public Health (2005), PhD in Oral Biology (2009) and Postdoctoral studies in Biological Sciences (2018) - Bauru School of Dentistry - University of São Paulo - Brazil. He has worked for 24 years in Public Health, experienced in RD&I - Health Technologies. Nowadays, he is the Research Director of TRIALS - Oral Health & Technologies and his current work areas are oral tissues regeneration and antiviral activity.